ICAD Inc
NASDAQ:ICAD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
ICAD Inc
Net Issuance of Common Stock
ICAD Inc
Net Issuance of Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ICAD Inc
NASDAQ:ICAD
|
Net Issuance of Common Stock
$2.3m
|
CAGR 3-Years
29%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
0%
|
|
|
Veeva Systems Inc
NYSE:VEEV
|
Net Issuance of Common Stock
$83.9m
|
CAGR 3-Years
24%
|
CAGR 5-Years
19%
|
CAGR 10-Years
30%
|
|
|
Inspire Medical Systems Inc
NYSE:INSP
|
Net Issuance of Common Stock
-$160.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Doximity Inc
NYSE:DOCS
|
Net Issuance of Common Stock
-$97m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Omnicell Inc
NASDAQ:OMCL
|
Net Issuance of Common Stock
-$61.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-6%
|
|
|
W
|
Waystar Holding Corp
NASDAQ:WAY
|
Net Issuance of Common Stock
$25.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
ICAD Inc
Glance View
iCAD, Inc. is a medical technology company, which engages in the provision cancer detection and therapy solutions. The company is headquartered in Nashua, New Hampshire and currently employs 136 full-time employees. The firm operates through two segments: Cancer Detection (Detection) and Cancer Therapy (Therapy). In the Detection segment, the Company’s solutions include advanced image analysis and workflow solutions enables healthcare professionals to serve patients by identifying pathologies and pinpointing the prevalent cancers earlier, and a comprehensive range of artificial intelligence and computer aided detection (CAD) systems and workflow solutions for two-dimension(2D) and third dimension (3D) mammography, magnetic resonance imaging (MRI) and computed tomography (CT). In the Therapy segment, the Company offers the Xoft System, an isotope-free cancer treatment platform technology. The Xoft System can be used for the treatment of early-stage breast cancer, endometrial cancer, cervical cancer and nonmelanoma skin cancer.
See Also
What is ICAD Inc's Net Issuance of Common Stock?
Net Issuance of Common Stock
2.3m
USD
Based on the financial report for Mar 31, 2025, ICAD Inc's Net Issuance of Common Stock amounts to 2.3m USD.
What is ICAD Inc's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 10Y
0%
The average annual Net Issuance of Common Stock growth rates for ICAD Inc have been 29% over the past three years , -25% over the past five years .
